Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age above or equal to 19 years at the time of Ryzodeg® initiation~* Type 2 diabetes mellitus patients~* Treated with any basal-insulin (plus/minus OAD (Oral Antidiabetic Drug)) or premix-insulin (plus/minus OAD) for at least 26 weeks prior to switching to Ryzodeg®~* Treated with Ryzodeg® (plus/minus OAD) for at least 26 weeks after switch from any basal insulin (plus/minus OAD) or premix insulin (plus/minus OAD)~* At least more than once documented medical visit for 26weeks (plus/minus 6 weeks) after Ryzodeg® initiation~* Minimum available data : age, type of diabetes at the time of Ryzodeg® initiation, HbA1c \[Three values: most recent value within 26 weeks (plus/minus 6 weeks) prior to Ryzodeg® initiation, a value of Ryzodeg® initiation date (plus/minus 6 week), and a value in the first 26 weeks (plus/minus 6 weeks) after Ryzodeg® initiation\]~* The decision to treat with Ryzodeg® was taken by treating physician independently from decision to include patient in study.~Exclusion Criteria:~* Patients treated with any diabetic investigational drug within 26 weeks before or after the initiation of Ryzodeg®~* Patients switching to Ryzodeg® below 26 weeks prior to the data collection date~* Patients not treated with any basal-insulin or premix-insulin at least 26 weeks prior to receiving Ryzodeg®~* Patients treated by continuous subcutaneous insulin infusion prior to receiving Ryzodeg®~* Pregnancy patient~* Patients not treated with the local licensed Ryzodeg®

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Ryzodeg (Type: None): Patients treated with any basal-insulin or premix-insulin for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg®.

Based on this trial design, predict the completion outcome and termination type (if applicable).